Devices for the identification of medical products

Information

  • Patent Grant
  • 8938898
  • Patent Number
    8,938,898
  • Date Filed
    Wednesday, December 6, 2006
    17 years ago
  • Date Issued
    Tuesday, January 27, 2015
    9 years ago
Abstract
Devices in which components of medical kits are carried are identifiable by means other than by the naked eye. The means for identification is attached to or integral with the device and may comprise raised and lowered surfaces that can be read by touch; serrations disposed on an edge or surface; a fluorescent coating viewable under infrared or ultraviolet light; or a pattern that is viewable using a thermal imaging device such as night vision goggles. A package for retaining a medical item includes an identifying element of a material that is selectively viewable in response to light attributes of the material. A device for the visual identification of a package containing a medical item includes an identifying element comprising a material that is visually discernible in reduced-light environments via the use of night vision devices.
Description
TECHNICAL FIELD

The present invention relates generally to medical products and, more particularly, to devices that facilitate the identification of medical products under low-light or no-light conditions.


BACKGROUND OF THE PRESENT INVENTION

Medical products in kit form are typically carried by military personnel, law enforcement personnel, and rescue personnel or other first responders into emergency situations. The various products chosen for inclusion in the kit are generally those used to at least temporarily address a wound and to stabilize a patient until the patient can be transported to a medical facility. These products generally include bandages, gauze, and compounds such as iodine solutions or other ointments that may be applied to wounds to improve septic conditions. Other products may include smelling salts, salt tablets, and devices for the automatic injection of compounds to treat anaphylactic shock (such as an EPIPEN).


First aid, particularly in military scenarios, must often be administered in less than favorable conditions such as in low light or in the dark. It is often impractical to provide artificial lighting in such scenarios because lighting may be unavailable or may attract hostile attention to both the wounded person and the caregiver. Especially under battle conditions, even the use of pen-type flashlights or similar devices may be susceptible to undesirable detection.


Situations may also occur in which a person's vision is impaired so that he/she may not be able to open the medical kit. A person may also be blinded as a result of foreign objects such as dust, smoke, chemical vapors, blood, or the like in addition to direct injury to the eyes. In these types of situations, no amount of light would enable the blinded person to see sufficiently to self-administer the needed aid. Furthermore, unless a caregiver is adequately equipped with the necessary paraphernalia (respirators or masks) to counter the effects of dust, smoke, chemical vapors, etc., the caregiver is also unlikely to be able to access the medical kit and the contents therein.


There is a current need for an improved manner of identifying emergency medical products under less than adequate lighting conditions or in situations in which vision is impaired.


Based on the foregoing, it is a general object of the present invention to provide devices that facilitate the identification of medical products under low-light or no-light conditions to allow for the application of such products to wounded personnel.


SUMMARY OF THE PRESENT INVENTION

Disclosed herein are devices that facilitate the identification of medical products under low-light or no-light conditions. Such conditions may be encountered in battle situations, in covert operations for purposes relating to reconnaissance or personnel and/or equipment transport, or as a result of climatic or environmental situations. The present invention is not limited in this regard, however, as other uses for the disclosed devices are within the scope of the invention. For example, the devices disclosed herein may also be utilized in conjunction with ammunition holders, communications apparatuses, tools, and the like.


In one aspect, the present invention resides in a pouch in which components of a medical kit are carried, the pouch being identifiable by means other than by the naked eye. The pouch is preferably closable using snaps, hook and loop material, zippers, or the like. The means for identification is attached to or integral with the pouch and may comprise raised and lowered surfaces that can be read by touch; serrations disposed on an edge or surface; a fluorescent coating viewable under infrared or ultraviolet light; or a pattern that is viewable using a thermal imaging device such as night vision goggles.


In another aspect, the present invention resides in a device for the identification of a medical item. The device is attachable to the medical item or to the packaging incorporating the item and includes a substrate and an arrangement of raised and lowered surfaces disposed thereon. The raised and lowered surfaces, which may be ridges, grooves, pimples, dimples, holes, Braille, or combinations thereof, define a pattern that is tactilely recognizable by a user when the user touches the raised and lowered surfaces.


In another aspect, the present invention resides in a device for the selective visual identification of a medical item. The device is attachable to the medical item and includes a substrate and a fluorescent ink disposed thereon. The fluorescent ink is visible under one of infrared light and ultraviolet light and is disposed on the substrate in a recognizable pattern (e.g., a medical cross).


In another aspect, the present invention resides in a device for the identification of a medical item, the device being attachable to the medical item. The device includes a substrate and a coating disposed thereon. The substrate is defined by a material having a first specific heat capacity, and the coating is defined by a material having a second specific heat capacity. The coating is disposed on the substrate in a recognizable pattern. The two specific heat capacities are different, which thereby allows one to be recognized relative to the other when viewed through a thermal imaging apparatus such as night vision goggles.


In another aspect, the present invention resides in a package for retaining a medical item. The package includes an identifying element of a material that is selectively viewable in response to light attributes of the material. The material is arranged to identify the contents of the package via lettering, colorings, graphics, combinations of the foregoing, and the like.


In another aspect, the present invention resides in a medical device that includes a hemostatic agent; a package in which the hemostatic agent is retained; and an identifying element on the package. The identifying element includes a material that is visually discernible in reduced light environments.


In another aspect, the present invention resides in a device for the visual identification of a package containing a medical item. Such a device includes an identifying element comprising a material that is visually discernible in reduced-light environments via the use of night vision devices. The identifying element may be formed into an indicia that indicates the contents of the package.


One advantage of the present invention is that a medical device can be utilized under hostile conditions without drawing unwanted attention. More specifically, by relying on tactile senses or the use of optical devices (such as those emitting infrared or ultraviolet light or those capable of reading thermal infrared radiation), a medical device can be found, opened, and applied as necessary for the treatment of a wound without compromising the position of the user.


Another advantage is that a medical device can be utilized under conditions in which the user is blinded. Rescue personnel, as well as law enforcement and military personnel, can rely on tactile abilities to locate specific items or to distinguish types of items for application in emergency situations such as heavy smoke, dust storms, and the like.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of the front of a medical kit having an identification device of the present invention.



FIG. 2 is a perspective view of the back of the medical kit of FIG. I showing the identification device of the present invention.



FIG. 3 is a perspective view of the identification device of the present invention in which the device is identifiable by tactile means.



FIG. 4 is a perspective view of the identification device of the present invention in which the device is identifiable by a selectively viewable means.



FIG. 5 is a perspective view of the identification device of the present invention in which the device is identifiable by a thermally-imagable means.



FIG. 6 is a perspective view of a package of blood clotting agent having the identification device of the present invention.



FIG. 7 is a perspective view of a package of blood clotting agent having a serrated edge as the identification device of the present invention.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As shown in FIGS. 1 and 2, a medical kit generally designated by the number 10 includes a bag or pouch 12 that functions as a receptacle for various components that make up the kit. Components that make up the kit 10 can include, but are not limited to, bandages, antiseptic compounds, tape, and packages or vials of blood clotting agents.


Referring specifically to FIG. 2, an attachment mechanism is also disposed on at least one wall 14 of the pouch 12 to facilitate the attachment of the pouch to a belt, vest, or other garment of the user. The attachment mechanism includes one or more straps 24 that are stitched or otherwise secured to the at least one wall 14 at one end thereof. The straps 24 can be looped around a belt or loops on a garment and attached back to the pouch 12 using snaps 26 (as shown) or any other suitable mechanism (e.g., hook and loop material, quick-release buckles, or the like). The straps 24 may also be utilized in conjunction with a MOLLE connection at the discretion of the user.


Referring to both FIGS. 1 and 2, the pouch 12 includes at least one identifying element 30 having a surface that can be discerned without the naked eye (e.g., by being identified through touch or by being selectively viewable through a device in response to colorings or certain light attributes (phosphorescence or luminescence)). The present invention is not limited in this regard, however, as the pouch 12 may alternatively (or additionally) include at least one identifying element 30 having a surface that can be discerned with the naked eye (e.g., by being identified in response to the certain light attributes (the phosphorescence or luminescence)). The identifying element 30 may form the surface or it may be attached to specific individual components of the kit 10, e.g., the packaging of individual components. Irrespective of where the identifying element 30 is located, the identifying element can be inspected by a user under low-light or no-light conditions to allow the user to determine the type of kit, the contents of the pouch 12, or the particular kit component. In embodiments in which the identifying element 30 is attached to the pouch 12, the identifying element can be located anywhere on the pouch, although the identifying element is preferably located on a top 18 of the pouch to indicate the point at which the pouch can be opened.


Referring now to FIG. 3, in one exemplary embodiment the identifying element 30 may be a device that provides a tactile sensation. The identifying element 30 may be in the form of a patch, tag, or label or the like embossed or otherwise made to have one or more raised surfaces 32 that, when touched by a user, allow the user to discern a pattern or recognizable indicia. Raised surfaces 32 of the identifying element 30 may be ridges, grooves, buttons, pimples, dimples, holes, conventional Braille nomenclature, combinations of the foregoing, or the like. Material from which the identifying element 30 is manufactured is a material that is not capable of easily being detected using conventional surveillance techniques. The material has a matte (or at least low gloss) finish in order to minimize detection by optical means. Materials include, but are not limited to, nylon, plastic, rubber, cloth, and the like.


Referring now to FIG. 4, in another exemplary embodiment the identifying element 30 is a surface that is selectively viewable. The surface may be disposed on a label, tag, patch, or the like for attachment to a bag or pouch. The present invention is not limited in this regard, however, as the surface of the identifying element 30 may be printed, painted, stamped, or inked directly onto a bag or pouch.


In addition to being visible with the naked eye under ambient light conditions, the identifying element 30 includes attributes that allow it to be visually discerned with the naked eye in low-light or no-light environments. Such attributes may be embodied in materials that include, but are not limited to, photoluminescent materials (e.g., an ink 36 or other material). The photoluminescent materials for use with the present invention include, but are not limited to, phosphorescent materials; fluorescent materials; paints, inks, or dyes that emit light when subjected to blacklight; chemical sources such as phenyl oxylate esters; combinations of the foregoing; and the like. Phosphorescent material is particularly useful for devices that are not intended to be used in situations that require stealth (e.g., civilian paramedic and rescue situations).


Also the ink 36 or other material may include a material that is visible under infrared or ultraviolet light or a material that allows the identifying element to be viewed in partial or complete darkness using night observation devices or night vision devices, e.g., night vision goggles and/or night vision monoculars. Passive night vision devices (those which pick up any light in the immediate area and amplify it thereby allowing it to be seen) are preferred over active night vision devices (those which project infrared light and produce an image from the light reflected back). The material may be photoluminescent or it may comprise paints, inks, or dyes of a particular color that facilitates the viewing of the material through night observation devices or night vision devices.


Identifying indicia such as text or other markings may be part of the identifying element 30. For example, a cross 38 or similar recognizable pattern may be superimposed on the ink 36 or material (or the ink or material may be superimposed on the cross) to allow a person to view the identifying element 30 under normal lighting or in low-light or complete darkness.


Referring to FIG. 5, in any embodiment, a portion of the identifying element 30 may be fabricated from a material having a specific heat capacity, thus allowing it to be imaged thermally. If the identifying element 30 is defined at least in part by a substrate 40 that includes a patterned coating 42 of a disparate material, differences in heat retention properties of the two materials can be simultaneously read and processed to produce an image. For example, if a coating of graphite (specific heat capacity of 0.720 Joules/gram/degree Kelvin) is deposited on brass (specific heat capacity of 0.377 Joules/gram/degree Kelvin), a thermal imaging apparatus can be utilized to view the pattern of the graphite coating (e.g., in the shape of a cross). The thermal imaging apparatus may be one capable of reading thermal infrared radiation, such as a night vision device.


Referring back to FIG. 4, the ink 36 (or other material) may include a material having a first specific heat capacity, and it may be deposited onto a substrate having a second specific heat capacity in such a way so as to define the recognizable pattern. Thus, the identifying element 30 may be read using any one of visible light, infrared or ultraviolet light, or thermal imaging, or it may be viewable as a result of the absorption and re-emission of light.


One of the components that make up the kit 10 may be a blood clotting agent in particle, granule, or powder form for application to a bleeding wound. Such a blood clotting agent is generally zeolite-based, although other types of blood clotting agents are within the scope of the present invention.


Referring now to FIG. 6, one embodiment of a package in which the blood clotting agent is sealed is shown at 50 and is hereinafter referred to as “package 50.” Package 50 includes the identifying element 30 as described above. The identifying element 30 may be a patch or the like configured to impart a tactile sensation, a label having a reflective ink or photoluminescent material as described herein, a marking defined by a reflective ink or photoluminescent material as described herein disposed on a surface of the package, a patterned coating capable of being thermally imaged, or a combination of the foregoing. The identifying element 30 may alternately or additionally be any indicia that is visible under ambient light conditions and visible under low-light or no-light conditions using active or passive night vision goggles or devices. The package 50 is typically a foil that in which the blood clotting agent is vacuum sealed.


Referring now to FIG. 7, another embodiment of a package in which the blood clotting agent is sealed is shown at 150 and is hereinafter referred to as “package 150.” Package 150 includes a serrated edge 31 as the identifying element. The serrated edge 31 is cut or otherwise formed at the edge of the material forming the package 150. Particularly when the package 150 is fabricated by joining two foil sheets along their respective edges, serrations may be cut into the joined edges. A user may, by touching the serrated edge 31, be able to identify the contents of the package 150. The present invention is not limited in this regard, however, as items other than blood clotting agents may be disposed in the package 150 having the serrated edge 31.


Although this invention has been shown and described with respect to the detailed embodiments thereof, it will be understood by those of skill in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed in the above detailed description, but that the invention will include all embodiments falling within the scope of the appended claims.

Claims
  • 1. A medical device comprising: a hemostatic agent;a package in which said hemostatic agent is retained, the package comprising a matte or low-gloss appearance to the naked eye; andan identifying element on said package, said identifying element comprising a material that provides visual accentuation when viewed through a night vision device in reduced light environments, the accentuation generally not visible to the naked eye both in normal light and in reduced light environments;wherein the identifying element is positioned on a location of the package where the package is to be opened.
  • 2. The medical device of claim 1, wherein said identifying element comprises a phosphorescent material.
  • 3. The medical device of claim 1, wherein said identifying element includes a material selected from the group consisting of fluorescent materials; paints, inks, and dyes that emit light when subjected to blacklight; phenyl oxylate esters; and combinations of the foregoing.
  • 4. The medical device of claim 1, wherein the medical device is retained in a pouch configured to retain medical products, wherein the pouch further comprises a second identifying element independently coupled to the pouch with respect to the package, wherein the second identifying element comprises a second material that provides visual accentuation when viewed through a night vision device in reduced light environments, the visual accentuation generally not visible to the naked eye in normal light environments and in reduced light environments.
  • 5. The medical device of claim 1, wherein the material comprises a luminescent material.
  • 6. The medical device of claim 1, wherein the material comprises a chemiluminescent material.
  • 7. The medical device of claim 6, wherein the chemiluminescent material comprises a phenyl oxylate ester.
  • 8. The medical device of claim 1, wherein the material comprises a fluorescent material.
  • 9. The medical device of claim 1, wherein the identifying element comprises a material that is visible under infrared light.
  • 10. The medical device of claim 1, wherein the identifying element comprises a material that is visible under ultraviolet light.
  • 11. The medical device of claim 1, wherein the identifying element comprises a material that emits infrared light.
  • 12. The medical device of claim 1, wherein the identifying element comprises a material that absorbs infrared light.
  • 13. The medical device of claim 1, wherein the identifying element comprises a material that emits ultraviolet light.
  • 14. The medical device of claim 1, wherein the identifying element comprises a material that absorbs ultraviolet light.
  • 15. The medical device of claim 1, wherein the identifying element comprises a material that has a different heat capacity than a heat capacity of a second feature of the identifying element.
  • 16. The medical device of claim 1, wherein said package further comprises an edge being defined by a plurality of surfaces, said surfaces defining a pattern that is recognizable by touching said surfaces.
  • 17. The medical device of claim 16, wherein said pattern is a plurality of serrations.
  • 18. The medical device of claim 1, wherein said identifying element is formed into an indicia that indicates the contents of the package.
  • 19. The medical device of claim 1, wherein said package protects said hemostatic agent from liquid and gaseous contamination.
  • 20. The medical device of claim 1, wherein said identifying element further comprises a pattern of raised and lowered surfaces.
  • 21. The medical device of claim 20, wherein said pattern of raised and lowered surfaces consists of ridges, grooves, buttons, dimples, pimples, holes, Braille nomenclature, or combinations of the foregoing.
CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Patent Application No. 60/796,121, filed on Apr. 27, 2006, the contents of which are incorporated herein by reference in their entirety.

US Referenced Citations (220)
Number Name Date Kind
2688586 Eberl et al. Sep 1954 A
2969145 Hannauer, Jr. Jan 1961 A
3122140 Crowe et al. Feb 1964 A
3181231 Breck May 1965 A
3189227 Hobbs et al. Jun 1965 A
3366578 Michalko Jan 1968 A
3386802 Michalko Jun 1968 A
3538508 Young Nov 1970 A
3550593 Kaufman Dec 1970 A
3658984 Kamp Apr 1972 A
3698392 Vogt et al. Oct 1972 A
3723352 Warner et al. Mar 1973 A
3763900 Solms-Baruth et al. Oct 1973 A
3979335 Golovko et al. Sep 1976 A
4373519 Errede et al. Feb 1983 A
4374044 Schaefer et al. Feb 1983 A
4379143 Sherry et al. Apr 1983 A
4435512 Ito et al. Mar 1984 A
4460642 Errede et al. Jul 1984 A
4514510 Alexander Apr 1985 A
4524064 Nambu Jun 1985 A
4525410 Hagiwara et al. Jun 1985 A
4569343 Kimura et al. Feb 1986 A
4626550 Hertzenberg Dec 1986 A
4631845 Samuel et al. Dec 1986 A
4651725 Kifune et al. Mar 1987 A
4717735 Stem Jan 1988 A
4728323 Matson Mar 1988 A
4748978 Kamp Jun 1988 A
4822349 Hursey et al. Apr 1989 A
4828081 Nordstrom et al. May 1989 A
4828832 DeCuellar et al. May 1989 A
4911898 Hagiwara et al. Mar 1990 A
4938958 Niira et al. Jul 1990 A
4956350 Mosbey Sep 1990 A
5140949 Chu et al. Aug 1992 A
5146932 McCabe Sep 1992 A
5474545 Chikazawa Dec 1995 A
5486195 Meyers et al. Jan 1996 A
5502042 Gruskin et al. Mar 1996 A
5538500 Peterson Jul 1996 A
5556699 Nira et al. Sep 1996 A
5578022 Scherson et al. Nov 1996 A
5597581 Kaessmann et al. Jan 1997 A
5599578 Butland Feb 1997 A
D386002 Hinkle Nov 1997 S
5696101 Wu et al. Dec 1997 A
5716337 McCabe et al. Feb 1998 A
5725551 Meyers et al. Mar 1998 A
5728451 Langley et al. Mar 1998 A
5766715 Garconnet Jun 1998 A
5788682 Maget Aug 1998 A
5801116 Cottrell et al. Sep 1998 A
5826543 Raymond et al. Oct 1998 A
5855570 Scherson et al. Jan 1999 A
5916511 Kotani et al. Jun 1999 A
5941897 Meyers Aug 1999 A
5964239 Loux et al. Oct 1999 A
5964349 Odagiri Oct 1999 A
5981052 Sugiyama Nov 1999 A
5993964 Nakajima Nov 1999 A
6037280 Edwards et al. Mar 2000 A
6060461 Drake May 2000 A
6086970 Ren Jul 2000 A
6123925 Barry et al. Sep 2000 A
6159232 Nowakowski Dec 2000 A
6187347 Patterson et al. Feb 2001 B1
6203512 Farris et al. Mar 2001 B1
6251423 Bradford Jun 2001 B1
6372333 Sugiyama et al. Apr 2002 B1
6428800 Greenspan et al. Aug 2002 B2
6450537 Norris Sep 2002 B2
6475470 Kayane et al. Nov 2002 B1
6481134 Aledo Nov 2002 B1
6486285 Fujita Nov 2002 B2
6495367 Isogawa et al. Dec 2002 B1
6523778 Key et al. Feb 2003 B2
6573419 Naimer Jun 2003 B2
6590337 Nishikawa et al. Jul 2003 B1
6622856 Gallo et al. Sep 2003 B2
6630140 Grunstein Oct 2003 B1
6685227 Merry et al. Feb 2004 B2
6700032 Gray Mar 2004 B1
6701649 Brosi Mar 2004 B1
6745720 Rasner et al. Jun 2004 B2
6890177 Dragan May 2005 B2
6998510 Buckman et al. Feb 2006 B2
7125821 Xu et al. Oct 2006 B2
7303759 Mershon Dec 2007 B2
7371403 McCarthy et al. May 2008 B2
7429252 Sarangapani Sep 2008 B2
7595429 Hursey Sep 2009 B2
7604819 Huey et al. Oct 2009 B2
7825133 Yi Nov 2010 B2
7858123 Stucky Dec 2010 B2
7968114 Huey et al. Jun 2011 B2
8063264 Spearman et al. Nov 2011 B2
8114433 Huey et al. Feb 2012 B2
8202532 Huey et al. Jun 2012 B2
8252318 Huey et al. Aug 2012 B2
8252344 Hursey Aug 2012 B2
8257731 Horn et al. Sep 2012 B2
8257732 Huey et al. Sep 2012 B2
8277837 Fischer et al. Oct 2012 B2
8383148 Huey et al. Feb 2013 B2
8460699 Huey et al. Jun 2013 B2
8512743 Horn et al. Aug 2013 B2
20020077653 Hudson et al. Jun 2002 A1
20020197302 Cochrum et al. Dec 2002 A1
20030018357 Luthra et al. Jan 2003 A1
20030133990 Hursey et al. Jul 2003 A1
20030175333 Shefer et al. Sep 2003 A1
20030176828 Buckman et al. Sep 2003 A1
20030199922 Buckman Oct 2003 A1
20030208150 Bruder et al. Nov 2003 A1
20030212357 Pace Nov 2003 A1
20040005350 Looney et al. Jan 2004 A1
20040013715 Wnek et al. Jan 2004 A1
20040038893 Ladner et al. Feb 2004 A1
20040121438 Quirk Jun 2004 A1
20040131820 Turner et al. Jul 2004 A1
20040166172 Rosati et al. Aug 2004 A1
20040166758 Reichmann et al. Aug 2004 A1
20040169033 Kuibira et al. Sep 2004 A1
20040243043 McCarthy et al. Dec 2004 A1
20050023956 Kwak et al. Feb 2005 A1
20050058721 Hursey Mar 2005 A1
20050070693 Hansen et al. Mar 2005 A1
20050074505 Hursey Apr 2005 A1
20050107826 Zhu et al. May 2005 A1
20050118230 Hill et al. Jun 2005 A1
20050119112 Pfenninger et al. Jun 2005 A1
20050137512 Campbell et al. Jun 2005 A1
20050143689 Ramsey, III Jun 2005 A1
20050147656 McCarthy et al. Jul 2005 A1
20050246009 Toner et al. Nov 2005 A1
20050248270 Ghosh et al. Nov 2005 A1
20050249899 Bonutti Nov 2005 A1
20060034935 Pronovost et al. Feb 2006 A1
20060078628 Koman et al. Apr 2006 A1
20060116635 Van Heugten Jun 2006 A1
20060121101 Ladizinsky Jun 2006 A1
20060141018 Cochrum et al. Jun 2006 A1
20060141060 Hursey et al. Jun 2006 A1
20060159733 Pendharkar et al. Jul 2006 A1
20060172000 Cullen et al. Aug 2006 A1
20060178609 Horn et al. Aug 2006 A1
20060193905 Ehringer et al. Aug 2006 A1
20060211965 Horn et al. Sep 2006 A1
20060211971 Horn et al. Sep 2006 A1
20060271094 Hudson et al. Nov 2006 A1
20060282046 Horn et al. Dec 2006 A1
20070016152 Karpowicz et al. Jan 2007 A1
20070031515 Stucky et al. Feb 2007 A1
20070065491 Huey et al. Mar 2007 A1
20070104768 Huey et al. May 2007 A1
20070104792 Jenkins May 2007 A1
20070134293 Huey et al. Jun 2007 A1
20070142783 Huey et al. Jun 2007 A1
20070154509 Wilcher et al. Jul 2007 A1
20070154510 Wilcher et al. Jul 2007 A1
20070154564 Stucky et al. Jul 2007 A1
20070160638 Mentkow et al. Jul 2007 A1
20070160653 Fischer et al. Jul 2007 A1
20070167971 Huey et al. Jul 2007 A1
20070251849 Lo et al. Nov 2007 A1
20070275073 Huey et al. Nov 2007 A1
20070276308 Huey et al. Nov 2007 A1
20070276345 Huey et al. Nov 2007 A1
20070281011 Jenkins et al. Dec 2007 A1
20080027365 Huey Jan 2008 A1
20080085300 Huey et al. Apr 2008 A1
20080097271 Lo et al. Apr 2008 A1
20080125686 Lo May 2008 A1
20080146984 Campbell et al. Jun 2008 A1
20080199539 Baker et al. Aug 2008 A1
20080206134 Lo et al. Aug 2008 A1
20080254146 Huey et al. Oct 2008 A1
20080254147 Huey et al. Oct 2008 A1
20080269658 Vinton et al. Oct 2008 A1
20080299226 Mentkow et al. Dec 2008 A1
20080317831 Lo Dec 2008 A1
20080319476 Ward et al. Dec 2008 A1
20090008261 Kotzeva et al. Jan 2009 A1
20090011394 Meglan et al. Jan 2009 A1
20090018479 McCarthy et al. Jan 2009 A1
20090043268 Eddy et al. Feb 2009 A1
20090047366 Bedard et al. Feb 2009 A1
20090053288 Eskridge, Jr. et al. Feb 2009 A1
20090074880 Ladizinsky Mar 2009 A1
20090076475 Ross et al. Mar 2009 A1
20090112170 Wells et al. Apr 2009 A1
20090123525 Bedard May 2009 A1
20090162406 Basadonna et al. Jun 2009 A1
20090186013 Stucky Jul 2009 A1
20090186071 Huey et al. Jul 2009 A1
20090232902 Liu et al. Sep 2009 A1
20090274769 Fregonese Nov 2009 A1
20090299253 Hursey Dec 2009 A1
20100035045 McAmish Feb 2010 A1
20100121244 Horn et al. May 2010 A1
20100184348 McAmish Jul 2010 A1
20100209531 Stucky et al. Aug 2010 A2
20100228174 Huey Sep 2010 A1
20100233248 Huey et al. Sep 2010 A1
20110015565 Hursey Jan 2011 A1
20110059287 McAmish Mar 2011 A1
20110064785 Daniels et al. Mar 2011 A1
20110150973 Bowlin et al. Jun 2011 A1
20110229849 Maurer et al. Sep 2011 A1
20110237994 Russ et al. Sep 2011 A1
20110268784 Huey Nov 2011 A1
20120004636 Lo Jan 2012 A1
20120070470 Pahari Mar 2012 A1
20120130296 Huey May 2012 A1
20120259262 Huey Oct 2012 A1
20130041332 Huey Feb 2013 A1
20130079695 Huey Mar 2013 A1
20130178778 Huey Jul 2013 A1
20130344131 Lo Dec 2013 A1
Foreign Referenced Citations (81)
Number Date Country
1223208 Jun 1987 CA
1970090 May 2007 CN
101104080 Jan 2008 CN
1114984 Mar 2008 CN
101541274 Sep 2009 CN
101687056 Mar 2010 CN
0 107 051 Sep 1983 EP
0 296 324 Dec 1988 EP
0296324 Dec 1988 EP
0 353 710 Feb 1990 EP
0826822 Mar 1998 EP
0888783 Jul 1999 EP
1159972 May 2001 EP
1 663 090 Jun 2006 EP
1690553 Aug 2006 EP
1714642 Oct 2006 EP
1 810 697 Jul 2007 EP
1810697 Jul 2007 EP
1 679 087 Jan 2010 EP
2 142 220 Jan 2010 EP
1 667 623 Nov 2010 EP
2 077 811 Nov 2010 EP
2 292 196 Mar 2011 EP
2 259 858 Mar 1993 GB
2314842 Jan 1998 GB
2 462 228 Feb 2010 GB
1135892 Jun 2010 HK
7088DELNP2009 Apr 2008 IN
241410 Jul 2010 IN
S59-62050 Sep 1984 JP
61145120 Jul 1986 JP
01-096558 Oct 1987 JP
2-45040 Feb 1990 JP
9-504719 May 1997 JP
2777279 Jul 1998 JP
10-337302 Dec 1998 JP
11-071228 Mar 1999 JP
11-178912 Jul 1999 JP
11-332909 Jul 1999 JP
2002-530157 Sep 2002 JP
2002-331024 Nov 2002 JP
2003-66045 Mar 2003 JP
2003-305079 Oct 2003 JP
2005-015537 Jan 2005 JP
2004123651 Jul 2006 JP
2011 00164 Sep 2004 TR
WO 9505445 Feb 1995 WO
WO 9512371 May 1995 WO
WO 9640285 Dec 1996 WO
WO 9913918 Mar 1999 WO
WO 0030694 Jun 2000 WO
WO 0066086 Nov 2000 WO
WO 0182896 Aug 2001 WO
WO 0197826 Dec 2001 WO
WO 0230479 Apr 2002 WO
WO 0230479 Apr 2002 WO
WO 02060367 Aug 2002 WO
WO 02074325 Sep 2002 WO
WO 03074566 Sep 2003 WO
WO 2005012493 Feb 2005 WO
WO 2005027808 Mar 2005 WO
WO 2005030279 Apr 2005 WO
WO 2005087280 Sep 2005 WO
WO 2005123170 Dec 2005 WO
WO 2006006140 Jan 2006 WO
WO 2006012218 Feb 2006 WO
WO 2006086557 Aug 2006 WO
WO 2006088912 Aug 2006 WO
WO 2006102008 Sep 2006 WO
WO 2006110393 Oct 2006 WO
WO 2007120342 Oct 2007 WO
WO 2008036225 Mar 2008 WO
WO 2008054566 May 2008 WO
WO 2008109160 Sep 2008 WO
WO 2008127497 Oct 2008 WO
WO 2008128149 Oct 2008 WO
WO 2008136806 Nov 2008 WO
WO 2008157536 Dec 2008 WO
WO 2009032884 Mar 2009 WO
WO 2009109194 Sep 2009 WO
WO 2009126917 Oct 2009 WO
Non-Patent Literature Citations (206)
Entry
Co-pending U.S. Appl. No. 10/939,687, filed Sep. 13, 2004.
Co-pending U.S. Appl. No. 10/939,869, filed Sep. 13, 2004.
Co-pending U.S. Appl. No. 11/023,869, filed Dec. 27, 2004.
Co-pending U.S. Appl. No. 11/054,918, filed Feb. 9, 2005.
Co-pending U.S. Appl. No. 11/082,716, filed Mar. 16, 2005.
Co-pending U.S. Appl. No. 11/303,607, filed Dec. 16, 2005.
Co-pending U.S. Appl. No. 11/404,126, filed Apr. 13, 2006.
Co-pending U.S. Appl. No. 11/544,238, filed Oct. 6, 2006.
Co-pending U.S. Appl. No. 11/584,079, filed Oct. 20, 2006.
Co-pending U.S. Appl. No. 11/586,968, filed Oct. 25, 2006.
Co-pending U.S. Appl. No. 11/590,427, filed Oct. 30, 2006.
Co-pending U.S. Appl. No. 11/592,477, filed Nov. 2, 2006.
Co-pending U.S. Appl. No. 11/606,617, filed Nov. 29, 2006.
Co-pending U.S. Appl. No. 11/633,687, filed Dec. 4, 2006.
Co-pending U.S. Appl. No. 11/634,673, filed Dec. 5, 2006.
Co-pending U.S. Appl. No. 11/654,409, filed Jan. 17, 2007.
Co-pending U.S. Appl. No. 11/710,106, filed Feb. 22, 2007.
Co-pending U.S. Appl. No. 11/715,057, filed Mar. 6, 2007.
Co-pending U.S. Appl. No. 12/101,336, filed Apr. 11, 2008.
Co-pending U.S. Appl. No. 12/101,346, filed Apr. 11, 2008.
Co-pending U.S. Appl. No. 12/140,356, filed Jun. 17, 2008.
Co-pending U.S. Appl. No. 12/204,129, filed Sep. 4, 2008.
U.S. Appl. No. 60/668,022, filed Apr. 4, 2005.
U.S. Appl. No. 60/708,206, filed Aug. 15, 2005.
U.S. Appl. No. 60/902,738, filed Feb. 21, 2007.
U.S. Appl. No. 60/955,854, filed Aug. 14, 2007.
U.S. Appl. No. 12/352,513, filed Jan. 12, 2009.
PCT Search Report for PCT/US2004/29809, dated Feb. 24, 2005.
International Search Report for Application No. PCT/US2004/029812, dated Jun. 14, 2005.
European Search Report for Application No. 05445078 dated Jun. 27, 2006.
Search Report for EP 05020602, dated Jul. 6, 2006.
PCT Search Report for PCT/US2005/046700, dated Jul. 6, 2006.
International Search Report for Application No. PCT/US2006/012487, dated Sep. 12, 2006.
International Search Report for Application No. PCT/US2006/004594, dated Nov. 3, 2006.
Search report for EP 06126082, dated May 11, 2007.
Supplementary Partial European Search Report for Application No. EP04783867 dated Jan. 29, 2008.
International Search Report for Application No. PCT/US2007/016509, dated Feb. 8, 2008.
International Search Report for EP 06123557, dated Feb. 29, 2008.
International Search Report for Application No. PCT/US2008/075191, dated Nov. 17, 2008.
Donald Voet & Judith Voet, “Molecular Physiology”, Biochemistry, p. 1087-1096, vol. 64, 1990, John Wiley & Sons.
Ima-Eu, Kaolin, Oct. 2006, p. 1-2.
The Merck Index; 1989, pp. 1596-1597, abstract 10021.
Hursey, et al., Bandage Using Molecular Sieves, Apr. 18, 2002, International Application Published Under the PCT, WO 02/30479 A1.
Alam, et al., Comparative Analysis of Hemostatic Agents in a Swine Model of Lethal Groin Injury, Jun. 2003, The Journal of Trauma Injury, Infection, and Critical Care, vol. 54, No. 6, pp. 1077-1082.
M. Gielen, Solid State Organometallic Chemistry: Methods and Applications Physical Organometallic Chemistry, 1999, New York John Wiley & Sons, Ltd. (UK), V. 2, p. 156.
Le Van Mao, Raymond et al. “Mesporous Aluminosilicates prepared from Zeolites by Treatment with Ammonium Fluorosilicate.” J. Mater. Chem. 1993. pp. 679-683, vol. 3, No. 6.
Dyer, A. et al. “Diffusion in heteroionic zeolites: Part 1. Diffusion of water in heteroionics natrolites.” Microporous and Mesoporous Materials. 1998, pp. 27-38, vol. 21.
Wright, J.K. et al., “Thermal Injury Resulting from Application of a Granular Mineral Hemostatic Agent.” The Journal of Trauma Injury, Infection, and Critical Care. 2004, pp. 224-230, vol. 57, No. 2.
Top, Ayben et al. “Silver, zinc, and copper exchange in a Na-clinoptilolite and resulting effect on antibacterial activity.” Applied Clay Science. 2004, pp. 13-19, vol. 27.
Office Action for U.S. Appl. No. 11/398,161 dated Apr. 30, 2008.
U.S. Appl. No. 10/939,687, filed Sep. 13, 2004 including prosecution history, including but not limited to Non-Final Rejection dated Oct. 16, 2006, Final Rejection dated May 24, 2007, Non-Final Rejection dated Sep. 6, 2007, Final Rejection dated Nov. 28, 2007 and Examiner's Answer to Appeal Brief.
U.S. Appl. No. 10/939,869, filed Sep. 13, 2004 including prosecution history, including but not limited to Non-Final Rejection dated Feb. 8, 2008, Non-Final Rejection dated Sep. 17, 2008 and Final Rejection dated Apr. 17, 2009.
U.S. Appl. No. 11/023,869, filed Dec. 27, 2004 including prosecution history, including but not limited to Requirement for Restriction/Election dated Mar. 31, 2008, Non-Final Rejection dated May 12, 2008 and Non-Final Rejection dated Dec. 11, 2008.
U.S. Appl. No. 11/054,918, filed Feb. 9, 2005 including prosecution history, including but not limited to Non-Final Office Rejection dated Mar. 18, 2008, Final Rejection dated Sep. 16, 2008 and Non-Final Rejection dated Mar. 9, 2009.
U.S. Appl. No. 11/082,716, filed Mar. 16, 2005 including prosecution history, including but not limited to Non-Final Rejection dated Oct. 9, 2008.
U.S. Appl. No. 11/303,607, filed Dec. 16, 2005 including prosecution history, including but not limited to Requirement for Restriction/Election dated Feb. 21, 2008, Non-Final Rejection dated Apr. 29, 2008 and Non-Final Rejection dated Sep. 8, 2008.
U.S. Appl. No. 11/404,126, filed Apr. 13, 2006 including prosecution history, including but not limited to Requirement for Restriction/Election dated Sep. 16, 2008 and Non-Final Rejection dated Dec. 3, 2008.
U.S. Appl. No. 11/544,238, filed Oct. 6, 2006 including prosecution history, including but not limited to Requirement for Restriction/Election dated Dec. 11, 2008; Non-Final Office Action dated May 29, 2009.
U.S. Appl. No. 11/584,079, filed Oct. 20, 2006 including prosecution history, including but not limited to Non-Final Rejection dated Apr. 6, 2009.
U.S. Appl. No. 11/590,427, filed Oct. 30, 2006 including prosecution history, including but not limited to Non-Final Rejection dated Aug. 19, 2008 and Final Rejection dated May 26, 2009.
U.S. Appl. No. 11/592,477, filed Nov. 2, 2006 including prosecution history, including but not limited to Non-Final Rejection dated May 28, 2008 and Final Rejection dated Dec. 22, 2008.
U.S. Appl. No. 11/633,687, filed Dec. 4, 2006 including prosecution history, including but not limited to Requirement for Restriction/Election dated Jun. 25, 2008 and Non-Final Rejection dated Sep. 4, 2998.
U.S Appl. No. 11/634,673, filed Dec. 5, 2006 including prosecution history, including but not limited to Requirement for Restriction/Election dated Apr. 9, 2008, Non-Final Rejection dated May 12, 2008, Final Rejection dated Nov. 14, 2008 and Non-Final Rejection dated May 21, 2009.
U.S. Appl. No. 11/715,057, filed Mar. 6, 2007 including prosecution history, including but not limited to Non-Final Rejection dated Aug. 20, 2008 and Final Rejection dated Apr. 2, 2009.
Alam, et al., Application of a Zeolite Hemostatic Agent Achieves 100% Survival in a Lethal Model of Complex Groin Injury in Swine, May 2004, The Journal of Trauma Injury, Infection, and Critical Care, vol. 56, pp. 974-983.
Aldrich—Handbook of Fine Chemicals and Laboratory Equipment, 2000-2001, pp. 1177-1178.
Analgesics and Anti-inflammatory agents 2004, retrieved from the internet on May 26, 2010, URL: http://web.archive.org/web/20040904151322/http://faculty.weber.edu/ewalker/Medicinal—Chemistry/topics/Analgesia—antiinflam/Analgesics—anti-inflamitory.htm.
Army halts use of new first aid item to study more, Seattle PI, Dec. 24, 2008.
Army halts use of WoundStat, http://stripes.com, Apr. 23, 2009.
Army pulls anti clotting agent after Fort Sam study finds threat, MySanAntonio Military, Dec. 24, 2008.
Baker, Sarah E. et al., Controlling Bioprocesses with Inorganic Surfaces: Layered Clay Hemostatic Agents, Department of Chemistry and Biochemistry, University of California, Santa Barbara, American Chemical Association 2007, 19, pp. 4390-4392 (3 pages total).
Basadonna, G., et al.: “A novel kaolin coated surgical gauze improves hemostasis both in vitro and in vivo”, Journal of Surgical Research, vol. 144, No. 2, Feb. 2008, p. 440, XP002534658, abstract.
Bethesda, MD, TraumaCure, Life-saving News for Battlefield Soldiers & Wounded Civilians FDA Clears Product to Stop Severe Bleeding, Sep. 10, 2007.
Butenas—Mechanism of factor Vlla-dependent coagulation in hemophilia blood, Hemostasis, Thrombosis, and Vascular Biology, Blood, Feb. 1, 2002—vol. 99, No. 3.
Carraway, et al., Comparison of a new mineral based hemostatic agent to a commercially available granular zeolite agent for hemostasis in a swine model of lethal extremity arterial hemorrhage, Resuscitation vol. 78, Issue 2, Aug. 2008.
Clay makers (raw materials) retrieved from the internet on Mar. 15, 2010, URL: http://web.archive.org/web/20020609175053/http://www.claymaker.com/ceramic—central/info/raw—clays.htm (year 2002, pp. 104).
Comparative Testing of Hemostatic Dressings in a Severe Groin Hemorrhage, Trauma & Resuscitative Medicine Department, NMRC, Aug. 2008.
Fruijtier-Polloth, “The safety of synthetic zeolites used in detergents”, Arch Toxicol (2009) 83:23-25.
Galan, et al.: “Technical properties of compound kaolin sample from griva (Macedonia, Greece)”, Applied Clay Science 1996 10:477-490.
Gibbar-Clements, et al.: “The Challenge of Warfarin Therapy”, JSTOR: The American Journal of Nursing,vol. 100, No. 3 (Mar. 2000), pp. 38-40.
HemCon Medical Technologies Inc. 501(k) Summary, GhitoGauze, Mar. 20, 2009.
James, “Silver Copper Zeolite Guinea Pig Sensitization Study—Beuhler Method”, Data Evaluation Report dated Oct. 3, 1989.
Kheirabadi, Army Assessment of New Hemostatic Products Suitable for Treating Combat Wounds, US Army Institute of Surgical Research, Aug. 11, 2008.
Kheirabadi, et al., Session IV-B, Paper 28, 8:20 a.m., Comparison of New Hemostatic Dressings with Currently Deployed Hemcon Bandage in a Model of Extremity Arterial Hemorrhage in Swine, Jan. 2009.
Kheirabadi, et al., The Journal of Trauma Injury, Infection, and Critical Care, Comparison of New Hemostatic Granules/Powders with Currently Deployed Hemostatic Products in a Lethal model of Extremity Arterial Hemorrhage in Swine, Feb. 2009, pp. 316-328.
Kheirabadi, Final Report, Title: Assessment of Efficacy of New Hemostatic Agents in a Model of Extremity Arterial Hemorrhage in Swine, U.S. Army Institute of Surgical Research, Ft. Sam Houston, TX 78234, Mar. 4, 2008.
Kovzun, I. G., et al.: “Application of nanosize clay-mineral systems in the complex therapy for hemophilia “A” patients”, Database HCAPLUS [online], XP002534657, retrieved from STN Database accession No. 2009:502758 abstract & Nanosistemi, Nanomateriali, Nanotekhnologii, vol. 6, No. 2, 2008.
Macrina, VCU's Research Enterprise, Structure and Resources, Oct. 23, 2008.
Margolis, J., “Initiation of Blood Coagulation by Glass and Related Surfaces,” J. Physiol., 1957, vol. 137, pp. 95-109.
Margolis, J., The Kaolin Clotting Time: A Rapid One-Stage Method for Diagnosis of Coagulation Defects, J. Clin. Pathol 1958, 11, pp. 406-409 (5 pages total).
Okada, et al.: “Preparation of zeolite-coated cordierite honeycombs prepared by an in situ crystallization method”, Science and Technology of Advanced Materials 2004 5:479-484.
O'Reilly et al.: “Studies on Coumarin Anticoagulant Drugs—Initiaion of Warfarin Therapy Without a Loading Dose”, Circulation by the American Heart Association, http://circ.ahajournals.org, 1968, 38, 169-177.
Ore-Medix, Traumastat Hemostatic Bandage, Aug. 7, 2008.
Permanent suspension of Woundstat use, https://email.z-medica.com, Apr. 17, 2009.
Reprinted related contents of US Alaract regarding QuikClot CombatGauze, Sep. 2008.
Sadler et al.: “Biochemstry and Genetics of Van Willebrand Factor”, Annual Review of Biochemistry; 1998. 67:395-424.
Scott Sackinger's Medical Devices Professional Summary dated Mar. 2009.
Sinter. (2004). In the New Penguin Dictionary of Science. London: Penguin. Retrieved May 7, 2009, from http://www.credoreference.com/entry/7463549/.
Tactical Combat Casualty Care Guidelines, Feb. 2009.
TraumaCure, Innovative Wound Care Products for Wound Care Solutions, Apr. 24, 2009.
Vitrify—(2001). In Chambers 21s5t Century Dictionary. London. Chambers Harrap. Retrieved May 7, 2009, from http://www.credoreference.com/entry/1236485/.
Wagner, Holly, “Topical Oxygen Helps Hard-To-Heal Wounds Heal Faster and Better,” Jan. 28, 2003, obtained from http://researchnews.osu.edu/archive/oxvwound.htm.
Ward, et al., The Journal of Trauma Injury, Infection, and Critical Care, Comparison of a New Hemostatic Agent to Current Combat Hemostatic Agents in a Swine Model of Lethal Extremity Arterial Hemorrhage, Aug. 2007, pp. 276-284.
Wound Stat, hhtp://shadowspear.com.
WoundStat found to be potentially hazardous, http://armytimes.com.
Wright, J. Barry et al.: “Wound management in an era of increasing bacterial antibiotic resistance: A role for topical silver treatment”, American Journal of Infection Control, vol. 26 (6), 1998, pp. 572-577.
Z-Medica Corporation 510(k) Summary, QuikClot eX, Oct. 4, 2007.
U.S. Appl. No. 11/054,918, filed Feb. 9, 2005, including prosecution history, including but not limited to Office Action dated Mar. 18, 2008.
U.S. Appl. No. 12/555,876, filed Sep. 9, 2009, including prosecution history, including but not limited to Office Action dated Dec. 28, 2010 and Office Action dated May 27, 2011.
U.S. Appl. No. 11/592,477, filed Nov. 2, 2006, including prosecution history, including but not limited to Office Action dated May 28, 2008, Office Action and dated Dec. 22, 2008 and Office Action dated Jun. 18, 2009.
U.S. Appl. No. 11/643,673, filed Dec. 5, 2006, including prosecution history, including but not limited to Office Action dated May 12, 2008, Office Action dated Nov. 14, 2008, Office Action dated May 21, 2009 and Office Action dated Mar. 25, 2010.
U.S. Appl. No. 11/590,427, filed Oct. 30, 2006, including prosecution history, including but not limited to Office Action dated Aug. 19, 2008, Office Action dated May 26, 2009, Office Action dated Jun. 7, 2010 and Office Action dated Apr. 5, 2011.
U.S. Appl. No. 12/417,802, filed Apr. 3, 2009, including prosecution history, including but not limited to Office Action dated Jun. 11, 2010 and Office Action dated Jan. 25, 2011.
U.S. Appl. No. 11/633,687, filed Dec. 4, 2006, including prosecution history, including but not limited to Office Action dated Sep. 4, 2008 and Office Action dated Jun. 12, 2009.
U.S. Appl. No. 11/654,409, filed Jan. 17, 2007, including prosecution history, including but not limited to Office Action dated Mar. 30, 2010 and Final Office Action dated Oct. 25, 2010.
U.S. Appl. No. 11/715,057, filed Mar. 6, 2007, including prosecution history, Including but not limited to Non-Final Rejection dated Aug. 20, 2008 and Final Rejection dated Apr. 2, 2009.
U.S. Appl. No. 12/581,782, filed Oct. 19, 2009, including prosecution history, including but not limited to Office Action dated Mar. 16, 2011.
U.S. Appl. No. 10/939,869, filed Sep. 13, 2004, including prosecution history, including but not limited to Office Action dated Feb. 8, 2008, Office Action date Sep. 17, 2008, Final Office Action dated Apr. 17, 2009, Final Office Action dated Apr. 1, 2010, Final Office Action date Dec. 12, 2010 and Office Action dated May 17, 2011.
U.S. Appl. No. 11/082,716, filed Mar. 16, 2005, including prosecution history, including but not limited to Office Action dated Oct. 9, 2008.
U.S. Appl. No. 11/303,607, filed Dec. 16, 2005, including prosecution history, including but not limited to Office Action dated Apr. 29, 2008 and Office Action dated Sep. 8, 2008.
U.S. Appl. No. 11/404,126, filed Apr. 13, 2006, including prosecution history, including but not limited to Office Action dated Dec. 3, 2008, Office Action dated Dec. 21, 2009 and Notice of Abandonment dated Oct. 8, 2010.
U.S. Appl. No. 11/586,986, filed Oct. 25, 2006, including prosecution history, including but not limited to Office Action dated Feb. 19, 2010 and Office Action dated Jun. 3, 2010.
U.S. Appl. No. 10/939,687, filed Sep. 13, 2004, Including prosecution history.
U.S. Appl. No. 11/023,869, filed Dec. 27, 2004, including prosecution history, including but not limited to Office Action dated May 12, 2008, Office Action dated Dec. 11, 2008, Office Action dated Jan. 26, 2010 and Office Action dated Sep. 16, 2010.
U.S. Appl. No. 11/606,617, filed Nov. 29, 2006, including prosecution history, including but not limited to Office Action dated Jun. 12, 2009.
U.S. Appl. No. 11/710,106, filed Feb. 22, 2007, including prosecution history, including but not limited to Office Action dated Oct. 1, 2010.
U.S. Appl. No. 12/101,336, filed Apr. 11, 2008, including prosecution history, including but not limited to Office Action dated Mar. 22, 2010 and Notice of Abandonment dated Oct. 7, 2010.
U.S. Appl. No. 12/101,346, filed Apr. 11, 2008, including prosecution history, including but not limited to Office Action dated Mar. 19, 2010 and Office Action dated Sep. 15, 2010.
U.S. Appl. No. 12/140,356, filed Jun. 17, 2008, including prosecution history, including but not limited to Office Action dated Sep. 28, 2010 and Office Action dated Mar. 21, 2011.
U.S. Appl. No. 12/204,129, filed Sep. 4, 2008, including prosecution history, including but not limited to Office Action dated May 31, 2011.
U.S. Appl. No. 11/544,238, filed Oct. 6, 2006, including prosecution history, including but not limited to Office Action dated May 29, 2009 and Office Action dated Jun. 25, 2010.
U.S. Appl. No. 12/503,481, filed Jul. 15, 2009, including prosecution history, including but not limited to Office Action dated Dec. 27, 2010 and Office Action dated Jul. 5, 2011.
U.S. Appl. No. 13/175,380, filed Jul. 1, 2011 including prosecution history.
Angeloni, V., M.D.: “How to care for your wound,” Heartland Dermatology & Skin Cancer P. C., copyright 2001, V. Angeloni MD.
U.S. Appl. No. 11/634,531, filed Dec. 6, 2006, including prosecution history, including but not limited to Office Action dated Feb. 4, 2009; Office Action dated Sep. 4, 2009, Office Action dated Mar. 29, 2010; Final Office Action dated Oct. 5, 2010; Office Action dated Jun. 23, 2011; BPAI Notice of Appeal dated Apr. 17, 2012, Appeal No. 2012-007306.
U.S. Appl. No. 12/204,129, filed Sep. 4, 2008, including prosecution history, including but not limited to Office Action dated May 31, 2011, Nov. 17, 2011, and Notice of Abandonment dated Jun. 20, 2012.
U.S. Appl. No. 12/555,876, filed Sep. 9, 2009, including prosecution history, including but not limited to Office Action dated Dec. 28, 2010, Office Action dated May 27, 2011, and Notice of Allowance dated Jun. 14, 2012.
U.S. Appl. No. 13/115,699, filed May 25, 2011 including prosecution history, including but not limited to Notice of Allowance dated May 30, 2012.
U.S. Appl. No. 13/526,431, filed Jun. 18, 2012 including prosecution history.
U.S. Appl. No. 10/939,869, filed Sep. 13, 2004, including prosecution history, including but not limited to Final Office Action dated May 17, 2011.
U.S. Appl. No. 12/140,356, filed Jun. 17, 2008, including prosecution history, including but not limited to Final Office Action dated Mar. 21, 2011.
U.S. Appl. No. 11/584,079, filed Oct. 20, 2006, including prosecution history, including but not limited to Office Action dated Apr. 6, 2009.
U.S. Appl. No. 11/634,673, filed Dec. 5, 2006, including prosecution history, including but not limited to Office Action dated Nov. 14, 2008.
U.S. Appl. No. 12/417,802, filed Apr. 3, 2009, including prosecution history, including but not limited to Office Action dated Jun. 11, 2010.
Webster's Dictionary definition of “expose” (1993).
U.S. Appl. No. 13/911,616, filed Jun. 6, 2013, including prosecution history.
Comparative Testing of Hemostatic Dressings in a Severe Groin Hemorrhage, Trauma & Resuscitative Medicine Department, NMRC, Aug. 2008 (Part 1 of 3, pp. 1-9).
Comparative Testing of Hemostatic Dressings in a Severe Groin Hemorrhage, Trauma & Resuscitative Medicine Department, NMRC, Aug. 2008 (Part 2 of 3, pp. 10-19).
Comparative Testing of Hemostatic Dressings in a Severe Groin Hemorrhage, Trauma & Resuscitative Medicine Department, NMRC, Aug. 2008 (Part 3 of 3, pp. 20-29).
U.S. Appl. No. 13/240,795, filed Sep. 22, 2011, including prosecution history.
U.S. Appl. No. 13/682,085, filed Nov. 20, 2012, including prosecution history.
Connor, William E.: “The Acceleration of Thrombus Formatin by Certain Fatty Acids,” Journal of Clinical Investigation, vol. 41, No. 6, 1962.
Hubbard, et al.: “Ionic charges of glass surfaces and other materials, and their possible role in the coagulation of blood,” Journal of Applied Physiology, Mar. 1, 1960, vol. 15, No. 2, pp. 265-270.
Ross, et al., “The Kaolin Minerals,” J. Amer. Ceramic Soc., vol. 13, issue 3, pp. 151 to 160, Mar. 1930.
Curasorb Calcium Alginate Dressings information page, http://www.kendallhq.com/kendallhealthcare/pageBuilder.aspx?webPageID=0&topicID=70966&xsl=xsl/productPagePrint.xsl (last accessed May 22, 2012).
Hollister Wound Care Restor Calcium Alginate Dressing, Silver instruction manual and information booklet, available at http://hollisterwoundcare.com/files/pdfs/ifus/Restore907814B407ColorBreak.pdf (last accessed May 22, 2012).
Medline Maxorb Extra AG Silver Alginate, http://www.medicaldepartmentstore.com/Medline-Maxorb-p/1560.htm (last accessed May 22, 2012).
“Mastering the Art of Innovative Thinking,” (color brochure) FMC BioPolymer, 2001 FMC Corporation.
Davis et al., 1H—NMR Study of Na Alginates Extracted from Sargassum spp. in Relation to Metal Biosorption, 110 Applied Biochemistry and Biotechnology 75 (2003).
Hahn, Lynn: “High temperature 1H NMR to determine the relative amounts of guluronate and mannuronate in the sodium alginate sample”, Intertek, ASA, Analytical Report, Report No. 60665 v 1, dated May 6, 2012.
Manugel® GMB alginate, FMC BioPolymer, Know how. It works.sm Product Specifications, 2011 FMC Corporation.
U.S. Appl. No. 10/939,869, filed Sep. 13, 2004 including prosecution history, including but not limited to Non-Final Rejection dated Feb. 8, 2008, Non-Final Rejection dated Sep. 17, 2008, Final Rejection dated Apr. 17, 2009, Final Office Action dated Apr. 1, 2010, Final Office Action dated Dec. 12, 2010; Final Office Action dated May 17, 2011 and Notice of Allowance dated Mar. 23, 2012.
U.S. Appl. No. 13/922,115, filed Jun. 19, 2013, including prosecution history.
EPO Extended Search Report, re EP Application No. 12163455, dated Sep. 12, 2012.
Lin et al., Synthesis of Hybridized Polyacrylic Acid-Kaolin Material and Its Superwater Absorbent Performance, J. Huaqiao Univ. (Nat. Sci.) Mar. 2000.
Long et al., Synthesis of Bentonite-superabsorbent Composite, J. Guilin Inst. Tech., Feb. 2004.
U.S. Appl. No. 13/593,310, filed Aug. 23, 2012, including prosecution history.
U.S. Appl. No. 13/595,932, filed Aug. 27, 2012, including prosecution history.
U.S. Appl. No. 13/598,381, filed Aug. 29, 2012, including prosecution history.
Dictionary of Traditional Chinese Medicine, “Astringents and Haemostatices,” The Commercial Press, Ltd., Apr. 1984 [ISBN 962 07 3051 8], pp. 216-217, total 4 pages.
Hempen, et al., A Materia Medica for Chinese Medicine, Plants minerals and animal products, Churchill Livingston Elsevier, 2009, [ISBN 978 0 443 10094 9], pp. 832-833 (Halloysitum rubrum, Chi shi zi), total 5 pages.
Hsu, et al. Orintal Materia Medica—a concise guide, pp. 310-311, 612-613, 32-34, total 12 pages. Oriental Healing Arts Institute, 1986. [ISBN 0 941 942 22 8].
Huang, Pharmacology of Chinese Herbs, Second Edition, p. 243 (Antidiarrheal Herbs), total 3 pages. CRC Press 1999. [ISBN 0 8493 1665 0].
Li; et al. Chinese Materia Medica—Combinations and Applications, Donica Publishing Ltd., 2002, [ISBN 1 901149 02 1], p. 622 (Ch. 18 Herbs for Promoting Astriction), total 5 pages.
Soine et al., Roger's Inorganic Pharmaceutical Chemistry, Lea & Febiger 1967, p. 462-463 (Aluminum and Aluminum Compounds), [QV744 S683r 1967] total 5 pages.
Wu, Jing-Nuan, “An Illustrated Chinese Materia Medica,” Oxford University Press, Inc. 2005 (13 pages).
Xinrong, Traditional Chinese Medicine, A Manual from A-Z, Symptoms, Therapy and Herbal Remedies, [ISBN 3 540 42846 1], p. 470 (total 3 pages), Springer-Verlag Berlin Heidelberg 2003.
Yanchi, The Essential Book of Traditional Chinese Medicine, vol. 2: Clinical Practice, p. 155-157 (Traditional Chinese Prescriptions), , 142-143 (Chinese Medicinal Herbs) total 8 pages. [ISBN 0 231 06518 3 9v.2] 1988.
U.S. Appl. No. 13/759,963, filed Feb. 5, 2013, including prosecution history.
Angeloni, V., M.D.: “How to care for your wound.”, Heartland Dermatology & Skin Cancer P. C., copyright 2001, V. Angeloni MD.
CA Office Action re Application No. 2,590,595, filed Dec. 22, 2005, Office Action dated Apr. 17, 2009.
CA Office Action re Application No. 2,677,606 filed Mar. 6, 2008, Office Action dated Jan. 26, 2012.
CA Office Action re Application No. 2,677,606 filed Mar. 6, 2008, Office Action dated Sep. 30, 2011.
Caloplast (Kaoline Poultrice), South African Electronic Package Inserts, Information presented by Malahyde Information Systems, Copyright 1996-1998, printed from home.intekom.com/pharm/allied/caloplst.html#INDICATIONS, two pages.
EPO Examination Report re EP 1 663 090, dated Dec. 8, 2011.
Griffin, John H., Role of surface in surface-dependent activation of Hageman factor (blood coagulation Factor XII), Proc. Natl. Acad. Sci. USA, vol. 75, No. 4, Apr. 1978, pp. 1998-2002 (5 pages total).
PCT International Search Report re Application No. PCT/US2010/041741, dated Nov. 26, 2010.
Reprinted related contents of U.S. Abstract regarding quickclot Combat Gauze (reprinted May 21, 2009).
Vlok, Marie E.: “Kaoline poultice”, Manual of Nursing, vol. 1, Basic Nursing, revised ninth edition, p. 269. Copyright Juta & Co, Ltd., Lansdowne, South Africa, first published 1962.
Wound Stat, http://shadowspear.com/vb/showthread.php?t=16586 dated Dec. 22, 2008, last accessed Apr. 16, 2009.
WoundStat found to be potentially hazardous, Army News, news from Iraq . . . , http://armytimes.com/news/2009/04/army—woundstat—042009w/, posted Apr. 20, 2009, last accessed Apr. 20, 2009.
U.S. Appl. No. 12/352,513, filed Jan. 12, 2009 including prosecution history.
U.S. Appl. No. 11/592,477, filed Nov. 2, 2006 including prosecution history, including but not limited to Non-Final Rejection dated May 28, 2008 and Final Rejection dated Dec. 22, 2008, Office Action dated Jun. 18, 2009 and Notice of Allowance dated Mar. 6, 2012.
U.S. Appl. No. 11/634,531, filed Dec. 6, 2006, including prosecution history, including but not limited to Office Action dated Feb. 4, 2009; Office Action dated Sep. 4, 2009, Office Action dated Mar. 29, 2010; Final Office Action dated Oct. 5, 2010; Office Action dated Jun. 23, 2011.
U.S. Appl. No. 12/204,129, filed Sep. 4, 2008, including prosecution history, including but not limited to Office Action dated May 31, 2011 and Nov. 17, 2011.
U.S. Appl. No. 12/510,203, filed Jul. 27, 2009, including prosecution history, including but not limited to, Office Action dated Sep. 26, 2011 and Feb. 24, 2012.
U.S. Appl. No. 12/611,830, filed Nov. 3, 2009, including prosecution history, including but not limited to Office Action dated Nov. 4, 2011 and Notice of Allowance dated Feb. 1, 2012 .
U.S. Appl. No. 60/668,022, filed Apr. 4, 2005, including prosecution history.
U.S. Appl. No. 60/708,206, filed Aug. 15, 2005, including prosecution history.
U.S. Appl. No. 60/902,738, filed Feb. 21, 2007, including prosecution history.
U.S. Appl. No. 60/955,854, filed Aug. 14, 2007, including prosecution history.
US Final Office Action re U.S. Appl. No. 10/939,869, filed Sep. 13, 2004, Office Action dated May 17, 2011.
US Office Action (Final) re U.S. Appl. No. 12/140,356, filed Jun. 17, 2008, Office Action dated Mar. 21, 2011.
US Office Action re U.S. Appl. No. 11/584,079, filed Oct. 20, 2006, Office Action dated Apr. 6, 2009.
US Office Action re U.S. Appl. No. 11/634,673, filed Dec. 5, 2006, Office Action dated Nov. 14, 2008.
US Office Action re U.S. Appl. No. 12/417,802, filed Apr. 3, 2009, Office Action dated Jun. 11, 2010.
Related Publications (1)
Number Date Country
20070251849 A1 Nov 2007 US
Provisional Applications (1)
Number Date Country
60796121 Apr 2006 US